{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:01Z","timestamp":1767134881096,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":77,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd008630.pub3","type":"reference-entry","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T00:54:50Z","timestamp":1361580890000},"source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome"],"prefix":"10.1002","author":[{"given":"Richard AC","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert DM","family":"Hadden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD008630.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1468-1331.2000.00096.x","article-title":"Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barr\u00e9 syndrome: a pilot study","volume":"7","author":"Bensa","year":"2000","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008630.pub3-BIB2|cit2","first-page":"52","article-title":"A pilot randomised, double-blind, placebo-controlled exploratory safety study of the use of interferon-beta 1a in the treatment of Guillain-Barr\u00e9 syndrome","volume":"8","author":"Pritchard","year":"2003","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"9","key":"10.1002\/14651858.CD008630.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","article-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Pritchard","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1212\/WNL.57.5.774","article-title":"CSF filtration is an effective treatment of Guillain-Barr\u00e9 syndrome: a randomized clinical trial","volume":"57","author":"Wollinsky","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub3-BIB5|cit5","first-page":"332","article-title":"Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome","volume":"20","author":"Zhang","year":"2000","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi\/Chinese Journal of Integrated Traditional & Western Medicine\/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB6|cit6","first-page":"186","article-title":"Cyclophosphamide in Landry-Guillain-Barr\u00e9 syndrome","volume":"2","author":"Ahuja","year":"1980","journal-title":"Acta Neurologica"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12028-011-9536-5","article-title":"Selective digestive tract decontamination decreases time on ventilator in Guillain-Barre syndrome","volume":"15","author":"Bos Eyssen","year":"2011","journal-title":"Neurocritical Care"},{"key":"10.1002\/14651858.CD008630.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(65)90479-4","article-title":"6-mercaptopurine in polyradiculoneuropathy","volume":"2","author":"Colin-Jones","year":"1965","journal-title":"Lancet"},{"issue":"9125","key":"10.1002\/14651858.CD008630.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(05)60466-7","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with interferon-beta","volume":"352","author":"Cr\u00e9ange","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00044011-199510060-00001","article-title":"L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients","volume":"10","author":"Grandis","year":"1995","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/jnnp.54.1.51","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with anti-T cell monoclonal antibodies","volume":"54","author":"Feasby","year":"1991","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB12|cit12","first-page":"253","article-title":"Clinical trial of a new coenzymatic complex (Ro 8-0743-4). [Italian]","volume":"62","author":"Francesconi","year":"1972","journal-title":"Clinica Terapeutica"},{"key":"10.1002\/14651858.CD008630.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(66)92410-X","article-title":"Mercaptopurine in polyradiculoneuropathy","volume":"i","author":"Gamstorp","year":"1966","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008630.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen","year":"2007","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD008630.pub3-BIB15|cit15","first-page":"S24","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with intravenous immunoglobulins and methylprednisolone combined with mycophenolate (CELLCEPT\u00ae) - a pilot study","volume":"10","author":"Garssen","year":"2005","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub3-BIB16|cit16","first-page":"22","article-title":"The use of pulsed and continuous UHF electrical fields in the rehabilitation of patients with the Guillain-Barre syndrome and other peripheral myelinopathies. [Russian]","volume":"95","author":"Gorbunov","year":"1995","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1378\/chest.104.2.547","article-title":"Neurologic disease requiring long-term ventilation. The role of selective decontamination of the digestive tract in preventing nosocomial infection","volume":"104","author":"Hammond","year":"1993","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF01706436","article-title":"Air fluidization therapy of pressure sores due to Guillain-Barre and Cushing syndrome","volume":"18","author":"Hilz","year":"1992","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD008630.pub3-BIB19|cit19","first-page":"119","article-title":"Ultraviolet rays for Guillain-Barre syndrome","volume":"21","author":"Huang","year":"1998","journal-title":"Chinese Journal of Physical Therapy"},{"key":"10.1002\/14651858.CD008630.pub3-BIB20|cit20","first-page":"123","article-title":"Ultraviolet radiation and oxygen enrichment self-blood transfusion therapy for Guillain-Barre syndrome","volume":"31","author":"Huang","year":"1998","journal-title":"Chinese Journal of Neurology"},{"issue":"26","key":"10.1002\/14651858.CD008630.pub3-BIB21|cit21","first-page":"714","article-title":"Treatment of polyneuropathies. Investigations on efficacy of ginkgo biloba extract EGb 761 in patients with polyneuropathy. [German]","volume":"69","author":"Husstedt","year":"1993","journal-title":"Zeitschrift fur Allgemeinmedizin"},{"key":"10.1002\/14651858.CD008630.pub3-BIB22|cit22","first-page":"178","article-title":"Ultraviolet rays for Guillain-Barr\u00e9 syndrome","volume":"21","author":"Li","year":"1998","journal-title":"Chinese Journal of Physical Therapy"},{"key":"10.1002\/14651858.CD008630.pub3-BIB23|cit23","first-page":"1293","article-title":"The safety and efficacy of 4-aminopyridine for motor weakness due to Guillain-Barr\u00e9 syndrome: a double-blind cross-over phase I drug trial","volume":"81","author":"Meythaler","year":"2000","journal-title":"Archives of Physical Medicine & Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/bmt.2008.81","article-title":"Rituximab-responsive Guillain-Barre syndrome following allogeneic hematopoietic SCT","volume":"42","author":"Ostronoff","year":"2008","journal-title":"Bone Marrow Transplantation"},{"issue":"7388","key":"10.1002\/14651858.CD008630.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(65)92091-X","article-title":"Polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome) treated with 6-mercaptopurine","volume":"1","author":"Palmer","year":"1965","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008630.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(66)90085-7","article-title":"Polyneuropathy treated with cytotoxic drugs","volume":"1","author":"Palmer","year":"1966","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0022-510X(76)90265-3","article-title":"Clinical effects of cyclophosphamide in Guillain-Barre polyneuritis","volume":"30","author":"Rosen","year":"1976","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000050798","article-title":"Successful treatment of Guillain-Barr\u00e9 syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin","volume":"46","author":"Schaller","year":"2001","journal-title":"European Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB29|cit29","first-page":"124","article-title":"Electroacupuncture at shu-points of the five zang-organs for treatment of the flaccidity syndrome","volume":"10","author":"Wang","year":"2006","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"7 (Suppl)","key":"10.1002\/14651858.CD008630.pub3-BIB30|cit30","first-page":"746","article-title":"Clinical trial of \"F.E.V. 300\". Apropos of 300 cases. [French]","volume":"12","author":"Warembourg","year":"1967","journal-title":"Lille Medical"},{"issue":"7678","key":"10.1002\/14651858.CD008630.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(70)92019-2","article-title":"Treatment of polyneuropathy with azathioprine","volume":"2","author":"Yuill","year":"1970","journal-title":"Lancet"},{"issue":"9-10","key":"10.1002\/14651858.CD008630.pub3-BIB32|cit32","first-page":"246","article-title":"Treatment of Guillain-Barr\u00e9 syndrome","volume":"117","author":"Zagar","year":"1995","journal-title":"Lijecnicki Vjesnik"},{"issue":"Suppl","key":"10.1002\/14651858.CD008630.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.53.2.409","article-title":"Residual physical outcome and daily living 3 to 6 years after Guillain-Barr\u00e9 syndrome","volume":"53","author":"Bernsen","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008630.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF00375050","article-title":"The acute paralysis in Guillain-Barr\u00e9 syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid","volume":"421","author":"Brinkmeier","year":"1992","journal-title":"Pflugers Archiv: European Journal of Physiology"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2340\/16501977-0007","article-title":"Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"39","author":"Bussman","year":"2007","journal-title":"Journal of Rehabilitation Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1212\/01.WNL.0000042423.36650.BD","article-title":"The pentapeptide QYNAD does not block voltage-gated sodium channels","volume":"60","author":"Cummins","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub3-BIB38|cit38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000022.pub3","article-title":"Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care","author":"D'Amico","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/09638280701352626","article-title":"Factors associated with health-related quality of life in patients with severe Guillain-Barr\u00e9 syndrome","volume":"30","author":"Demir","year":"2008","journal-title":"Disability and Rehabilitation"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1212\/WNL.57.5.753","article-title":"Drain the roots: a new treatment for Guillain-Barr\u00e9 syndrome?","volume":"57","author":"Feasby","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-151-4-200908180-00005","article-title":"Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial","volume":"151","author":"Goldbach-Mansky","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","volume":"44","author":"Hadden","year":"1998","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD008630.pub3-BIB43|cit43","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"8093","key":"10.1002\/14651858.CD008630.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008630.pub3-BIB45|cit45","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4471-3175-5","volume-title":"Guillain-Barr\u00e9 Syndrome","author":"Hughes","year":"1990"},{"issue":"9497","key":"10.1002\/14651858.CD008630.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"issue":"Pt 9","key":"10.1002\/14651858.CD008630.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB48|cit48","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e3181d1a862","article-title":"Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"74","author":"Hughes","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008630.pub3-BIB50|cit50","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008630.pub3-BIB51|cit51","first-page":"CD001446","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","volume":"8","author":"Hughes","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00415-009-5400-3","article-title":"Guillain-Barre syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?","volume":"257","author":"Jaso","year":"2010","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3748\/wjg.14.318","article-title":"Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection","volume":"14","author":"Khiani","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/brain\/awq179","article-title":"Functional role of brain derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis","volume":"133","author":"Linker","year":"2010","journal-title":"Brain"},{"key":"10.1002\/14651858.CD008630.pub3-BIB55|cit55","unstructured":"Ludolph A (Department of Neurology University of Ulm) Email to Prof RAC Hughes dated 1st September 2010 Located at Cochrane Neuromuscular Disease Group Editorial Base"},{"issue":"11","key":"10.1002\/14651858.CD008630.pub3-BIB56|cit56","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003280.pub3","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Mahdi-Rogers","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/kep120","article-title":"Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression","volume":"48","author":"Mak","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB58|cit58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006263.pub2","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1212\/WNL.53.8.1648","article-title":"Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group","volume":"53","author":"Merkies","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1017\/S0317167100004248","article-title":"The pentapeptide QYNAD does not inhibit neuronal network activity","volume":"32","author":"Otto","year":"2005","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"9047","key":"10.1002\/14651858.CD008630.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008630.pub3-BIB62|cit62","first-page":"CD001798","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Raphael","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008630.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","article-title":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","volume":"119","author":"Ravaglia","year":"2008","journal-title":"Clinical Neurophysiology"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jnnp.64.1.74","article-title":"Epidemiological study of Guillain-Barr\u00e9 syndrome in south east England","volume":"64","author":"Rees","year":"1998","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD008630.pub3-BIB65|cit65","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub3-BIB66|cit66","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis","author":"Rice","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008630.pub3-BIB67|cit67","unstructured":"Roche Products Limited Cellcept Summary of Product Characteristics last updated on the eMC: 27\/10\/2009 Electronic Medicines Compendium (eMC) YR:2010"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain-Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00415-010-5521-8","article-title":"Guillain-Barr\u00e9 syndrome after short-course efalizumab treatment","volume":"257","author":"Turatti","year":"2010","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD008630.pub3-BIB71|cit71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial","volume":"363","author":"Koningsveld","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD008630.pub3-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1001\/archderm.144.10.1396","article-title":"Efalizumab-associated Guillain-Barr\u00e9 syndrome","volume":"144","author":"Victor","year":"2008","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD008630.pub3-BIB73|cit73","first-page":"95","article-title":"Clinical experiences with CSF filtration in Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy and multiple sclerosis","volume":"9","author":"Wollinsky","year":"1995","journal-title":"Neuropsychiatrie"},{"issue":"24","key":"10.1002\/14651858.CD008630.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10428190701760003","article-title":"Guillain-Barr\u00e9 syndrome after transplantation","volume":"49","author":"Zhang","year":"2008","journal-title":"Leukaemia and Lymphoma"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub3-BIB76|cit76","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barr\u00e9 syndrome","author":"Hughes","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub3-BIB77|cit77","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008630.pub2","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barr\u00e9 syndrome","author":"Hughes","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008630.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008630.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:22:06Z","timestamp":1628533326000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008630.pub3"}},"subtitle":[],"editor":[{"given":"Richard AC","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":77,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008630.pub3","relation":{},"subject":[],"published":{"date-parts":[[2013,2,28]]}}}